YTENQ (Yield10 Bioscience) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Apr. 27, 2025)

View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Yield10 Bioscience's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Yield10 Bioscience's Future 3-5Y EPS without NRI Growth Rate

For the Agricultural Inputs subindustry, Yield10 Bioscience's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yield10 Bioscience's Future 3-5Y EPS without NRI Growth Rate Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Yield10 Bioscience (OTCPK:YTENQ) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Yield10 Bioscience Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Yield10 Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (OTCPK:YTENQ) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Presidential Way, Woburn, MA, USA, 01801

Website

https://www.yield10bio.com

Yield10 Bioscience Inc is an agricultural bioscience company. It is leveraging advanced genetics to develop the oilseed Camelina sativa as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton	director	1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser	officer: VP Fin and CAO
Lynne H Brum	officer: VP Planning and Comms	21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell	officer: VP Research & CSO	C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey	director	C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples	director, officer: Pres & CEO	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin	director	21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully	10 percent owner	C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038